Abstract-Creatine, a compound that is critical for energy metabolism of nervous cells, crosses the blood-brain barrier (BBB) and the neuronal plasma membrane with difficulty, and only using its specific transporter. In the hereditary condition where the creatine transporter is defective (creatine transporter deficiency) there is no creatine in the brain, and administration of creatine is useless lacking the transporter. The disease is severe and incurable. Creatine-derived molecules that could cross BBB and plasma membrane independently of the transporter might be useful to cure this condition. Moreover, such molecules could be useful also in stroke and other brain ischemic conditions. In this paper, we investigated three creatine salts, creatine ascorbate, creatine gluconate and creatine glucose. Of these, creatine glucose was ineffective after transporter block with guanidine acetic acid (GPA) administration. Creatine ascorbate was not superior to creatine in increasing tissue creatine and phosphocreatine content after transporter impairment, however even after such impairment it delayed synaptic failure during anoxia. Finally, creatine gluconate was superior to creatine in increasing tissue content of creatine after transporter block and slowed down PS disappearance during anoxia, an effect that creatine did not have. These findings suggest that coupling creatine to molecules having a specific transporter may be a useful strategy in creatine transporter deficiency. In particular, creatine ascorbate has effects comparable to those of creatine in normal conditions, while being superior to it under conditions of missing or impaired creatine transporter. Ó 2016 The Authors. Published by Elsevier Ltd. on behalf of IBRO. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
INTRODUCTION

20
Creatine or Methyl Guanidino-Acetic Acid is an amino 21 acid that is central to the energetic metabolism of the 22 cells, particularly those with high energy requirements 23 like neurons (Be´ard and Braissant, 2010) . Inside the cells To reach the brain, creatine synthesized by the body or 35 taken up with the diet must cross the blood-brain barrier 36 (BBB), and to do so it needs a specific transporter (cre-37 atine transporter or CrT) codified by the gene SLC6A8 38 (Christie, 2007) . Once across the BBB, it needs again 39 the same transporter to cross the cell plasma membrane 40 and enter brain neurons (Lunardi et al., 2006) . Exogenous 41 creatine may be useful for human therapy in two main dis-can be used to restore its brain content in those con- structure that can cross the BBB and at the same time 61 maintain a biological activity similar to that of creatine 62 (Balestrino et al., 2002) . While such molecules have 63 indeed been researched, even by our laboratory 64 (Perasso et al., 2008 (Perasso et al., , 2009 Adriano et al., 2011; Enrico 65 et al., 2013) (Perasso et al., 2013) . Specifically, we tested three differ- As a model, we used mouse hippocampal slices. we used before in our research (Perasso et al., 2008) procedure" section). 113 We analyzed these creatine derivatives in to certify the purity of the final products. We also 115 investigated the stability of these salts in saline solution. 116 We found that creatine glucose content is reduced to 117 about half after about 75 min ( Fig. 2A) (Fig. 3A) . Moreover, all of them 136 were also able to increase phosphocreatine concentration 137 except creatine itself, which showed only a not significant 138 trend toward increase (Fig. 3B ).
139
Effects after block of the creatine transporter concentration of creatine ascorbate is reduced to about half after 40 min. After 3 h, only 5/7% of the initial compound amount is still present. (C) creatine glucose is the most stable of the three compounds, content is reduced to half after 180 min. After 3 h, 60% of the initial compound amount is still present. creatine more than creatine itself (Fig. 4A) In these experiments, we tested creatine, creatine- (Simpson et al., 1994) . GLUT 2 appears to be widely 202 expressed in all brain regions, but at apparently low levels, 203 GLUT 4 is expressed in the pituitary, the hypothalamus and 204 the medulla (Brant et al., 1993) . GLUT1 have two isoform: human microvessels (Dick et al., 1984 increase phosphocreatine concentration (Fig. 4B ).
256
Consequently, and as expected, creatine was not able 257 to delay PS disappearance during anoxia after 258 transporter impairment (Fig. 6 ). decayed slowly is aqueous solution (Fig. 2) , a finding that 302 is consistent with the biological effects we found.
303
We do not exclude a partial dissociation of the salts in 304 two components into ACSF medium. However, this could (Fig. 4) . Moreover, a specific compound (creatine 310 gluconate) raises the creatine levels more than creatine 311 itself when the transporter is blocked (Fig. 5) To investigate the stability of the three creatine salts, To functionally inactivate the creatine transporter we used 417 guanidinopropionic acid (GPA) as described in our E. Adriano et al. / Neuroscience xxx (2016) xxx-xxxprevious work (Lunardi et al., 2006 content by about 50% (Lunardi et al., 2006, Fig. 4 ) and 428 reduced uptake of creatine by about the same measure 429 (Lunardi et al., 2006 , Fig. 5A ).
430
Study of the neuroprotective effect
431
The neuroprotective effect of the compounds deriving 432 from creatine was studied using electrophysiological 433 techniques on in vitro hippocampus slices. We followed 434 a published method (Whittingham and Lipton, 1981 ) that 435 we previously used in our laboratory (Balestrino et al., 436 1999; Perasso et al., 2008) . It is based on Whittingham ATP dependant (Whittingham and Lipton, 1981 Whittingham and Lipton (1981) showed that in brain slices The quantitative analysis of metabolites was carried out, 527 with slight modification respect to a previous published 528 paper (Lunardi et al., 2008) 
